CYP17A1 and sleep disorder: In all large phase III trials investigating novel hormonal agents plus ADT, compared to placebo or standard of care (SOC), sleep disorders have not been reported or assessed as independent adverse events (Table 2), as is also not the case in trials of the CYP17 inhibitor Abiraterone (Table 3).